• AAM praises Supreme Court Ruling granting access to biosimilars europeanpharmaceuticalreview
    June 20, 2017
    The Association for Accessible Medicines (AAM) applauded the US Supreme Court’s decision this week in Sandoz Inc. v. Amgen Inc. that will help speed patient access to biosimilar versions of expensive brand-name biologic medicines.
PharmaSources Customer Service